《豆制品可保护性预防乳腺癌》

  • 来源专题:食物与营养
  • 编译者: 潘淑春
  • 发布时间:2016-06-08
  • A study from Shanghai involving more than 70,000 healthy women shows that consuming soyfoods reduces risk of breast cancer. The study is good news for Western women and girls because they, too, can derive health benefits and reduce their risk of breast cancer by starting to incorporate higher amounts of soyfoods into their diets.

    After following 70,000 study participants for more than 13 years, the Shanghai study found that 1,034 participants developed breast cancer. Here are some details from the study.

    Consuming approximately one-and-a-half servings of soyfoods per day during adolescence was associated with a nearly 50 percent lower risk of developing breast cancer before menopause..

    Consuming approximately two servings of soyfoods per day during adulthood was associated with a one-third reduction in the risk of postmenopausal breast cancer..

    Consuming soyfoods early in life was not protective against breast cancer after menopause. The investigators who conducted the study reasoned that the protective effects of consuming soy early in life are fully present during the premenopausal period, so there is no further protection against breast cancer after menopause..

    The study from Shanghai is relevant for American women—whose diets have not traditionally included soy— because adult soy intake was protective against breast cancer only among women who consumed little soy when they were young. By doing so now, women can reduce their risk of breast cancer. Also, young girls who consume soy will significantly reduce their risk later in life. Current U.S. breast cancer statistics show that about one in eight American women will develop invasive breast cancer over the course of her lifetime.

    The Soyfoods Council reminds you that one serving of soyfoods—including soymilk and edamame—provides approximately 7 to 15 grams of high-quality plant-based protein. Unlike many commonly consumed protein-rich foods, soyfoods are also cholesterol-free and low in saturated fat.

相关报告
  • 《纳米颗粒的目标是早期乳腺癌转移》

    • 来源专题:纳米科技
    • 编译者:郭文姣
    • 发布时间:2017-10-03
    • 尽管在癌症治疗方面取得了进展,但在癌症转移之后治疗癌症仍然是一个未得到满足的临床挑战。在本研究中,我们展示了100纳米脂质体的目标是三阴性的鼠乳腺癌转移。转移性乳腺癌是由b/c小鼠在试验中诱导的,通过对4T1细胞的尾静脉注射,或在移植了原发性肿瘤异种移植后自发进行的。为了追踪他们在体内的生物分布,脂质体被标记为多模态诊断制剂,包括用于全动物荧光成像的indocyanine green和rhodamine,用于磁共振成像(MRI)的gadolinium,以及用于定量的生物分布分析的europium。在转移过程中,脂质体的积累达到了24小时后的峰值,这与在原发性肿瘤中达到峰值的时间相似。对转移性组织的脂质体的效率比非脂质体的效率高了4.5倍。在转移性进展的早期阶段发现了脂质体,包括直径小于2毫米的转移病灶。令人惊讶的是,虽然纳米颗粒可以治疗乳腺癌的转移,但在转移前的位置上,它们也可能会被发现,在转移的前几天,通过核磁共振成像或组织学上的组织,可以看到癌细胞转移。这项研究强调了治疗转移性癌症的诊断和治疗纳米粒子的前景,甚至可能是为了防止转移性传播的发生,因为它是针对转移性的利基。 ——文章发布于2017年10月2日
  • 《Ribociclib首次获批用于治疗乳腺癌》

    • 来源专题:重大新药创制—研发动态
    • 编译者:杜慧
    • 发布时间:2017-04-20
    • Ribociclib 是由诺华研制的,用于癌症治疗的一种口服、 小分子细胞周期蛋白激酶4 和 6抑制剂(CDK) 。CDKs在细胞周期和细胞增殖中发挥重要作用,ribociclib 通过抑制CDKs干扰细胞G1期而发挥作用。Ribociclib与芳香化酶抑制剂联用刚获FDA批准作为一线药物用于治疗晚期乳腺癌,且已将同样的适应症报批欧盟。Ribociclib 目前正在进行进一步的 III 期临床试验,也在针对各种类型固体肿瘤和血液系统恶性肿瘤评估I期或II期试验。